1306137-08-5Relevant academic research and scientific papers
Homoleptic iron(II) and cobalt(II) bis(phosphoranimide) complexes for the selective hydrofunctionalization of unsaturated molecules
Bai, Tao,Janes, Trevor,Song, Datong
supporting information, p. 12408 - 12412 (2017/10/06)
Low-coordinate homoleptic bulky M2(NPtBu3)4 (M = Fe (A), Co (B)) complexes were synthesized and characterized as dimeric structures by crystallographic studies. The iron complex A can catalyze the hydroboration reaction of aldehydes and ketones. The cobalt complex B outperformed its iron counterpart in hydrogenations of several typical alkenes and alkynes under mild conditions. Poisoning experiments indicate that the Co(ii)/HBpin catalytic system could be homogeneous.
Aluminum Monohydride Catalyzed Selective Hydroboration of Carbonyl Compounds
Jakhar, Vineet Kumar,Barman, Milan Kr.,Nembenna, Sharanappa
supporting information, p. 4710 - 4713 (2016/09/28)
The well-defined aluminum monohydride compound [{(2,4,6-Me3-C6H2)NC(Me)}2(Me)(H)]AlH·(NMe2Et) (1) catalyzes hydroboration of a wide range of aldehydes and ketones under mild reaction conditions. Moreover, compound 1 displayed chemoselective hydroboration of aldehydes over ketones at rt.
Discovery of a novel oxime ether scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists
Li, Zheng,Yang, Jianyong,Gu, Weijie,Cao, Guoshen,Fu, Xiaoting,Sun, Xuedan,Zhang, Yu,Jin, Hui,Huang, Wenlong,Qian, Hai
, p. 46356 - 46365 (2016/06/09)
The free fatty acid receptor 1 (FFA1) plays a key role in amplifying glucose-stimulated insulin secretion in pancreatic β-cells. Most of the reported FFA1 agonists contain a biphenyl scaffold, which is associated with toxicity as verified by Daiichi Sankyo. Herein, we describe the systematic exploration of a non-biphenyl scaffold to improve the druggability of GW9508 (β-oxidation, Fsp3 = 0.13, tPSA = 58.5 ?2) directed by Fsp3 and tPSA values. All these optimizations ultimately led to the identification of compound 21, an unconventional agonist (EC50 = 72.5 nM) bearing a methyl oxime ether scaffold. Moreover, compound 21 revealed improved drug-like properties (Fsp3 = 0.23, tPSA = 86.6 ?2) when compared to GW9508 (Fsp3 = 0.13, tPSA = 58.5 ?2) and an even higher binding efficiency index (BEI = 15.3) than TAK-875 (BEI = 14.3). Further pharmacological studies suggested that compound 21 has a considerable hypoglycemic effect in both normal and type 2 diabetic mice with a low risk of hypoglycemia. In addition, the docking study promoted our understanding of the ligand-binding pocket. This information might help towards the design of more promising new molecular entities.
Novel oxime ether derivative and preparation method thereof and application of derivative by serving as drug
-
Paragraph 0182; 0184; 0185, (2016/10/08)
The invention relates to a novel oxime ether derivative shown as a general formula (I) (please see the formula in the description) and a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of a drug for treating diabetes and a metabolic syndrome. The oxime ether derivative has the excellent in-vivo hypoglycemic activity and can be used for preventing or treating the diabetes.
Ruthenium Catalyzed Selective Hydroboration of Carbonyl Compounds
Kaithal, Akash,Chatterjee, Basujit,Gunanathan, Chidambaram
supporting information, p. 4790 - 4793 (2015/10/12)
Using the [Ru(p-cymene)Cl2]2 (1) complex, catalytic hydroboration of aldehydes and ketones with pinacolborane under neat and mild conditions is reported. At rt, chemoselective hydroboration of aldehydes over the ketones is also attained. Mechanistic studies confirmed the immediate formation of monohydride bridged dinuclear complex [{(μ6-p-cymene)RuCl}2(μ-H-μ-Cl)] (1b) from the reaction of 1 with pinacolborane, which catalyzed the highly efficient hydroboration reactions. The catalytic cycle containing mononuclear Ru-H species and intramolecular 1,3-hydride transfer is postulated.
SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF
-
Page/Page column 119, (2015/03/16)
The present invention generally relates to substituted heterocyclic derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as G-protein coupled receptor (GPR) agonists, particularly as GPR40 agonists and methods of using these compounds in the treatment of GPR40 mediated diseases or conditions such as Type 2 diabetes, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Selective aldehyde reduction in ketoaldehydes with NaBH4-Na 2CO3-H2O at room temperatures
Chandrasekhar, Sosale,Shrinidhi, Annadka
, p. 2051 - 2056 (2014/07/07)
A variety of aliphatic and aromatic ketoaldehydes were reduced to the corresponding ketoalcohols with a mixture of sodium borohydride (1.2 equivalents) and sodium carbonate (sixfold molar excess) in water. Reactions were performed at room temperatures(typically) 2 h, and yields of isolated products generally ranged from 70% to 85%. A bis-carbonate-borane complex, [(BH3)2CO2]2- 2Na+, possibly formed from the reagent mixture, is likely the active reductant. The moderated reactivity of this acylborane species would explain the chemoselectivity observed in the reactions. The readily available reagents and the mild aqueous conditions make for ease of operation and environmental compatibility, and make a useful addition to available methodology. Copyright
AGONISTS OF GPR40
-
Page/Page column 175; 176-177, (2012/02/05)
The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are there-fore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.
